{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:42:46Z","timestamp":1792618966509,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.vhri.2024.101004","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T20:47:41Z","timestamp":1719434861000},"page":"101004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cost-Utility Analysis of Maintenance Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Non\u2013Small Cell Lung Cancer in Jordan"],"prefix":"10.1016","volume":"43","author":[{"given":"Abeer","family":"Al Rabayah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Al Froukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Sawalha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maali","family":"Al Shnekat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad M.","family":"Jaddoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2024.101004_bib3","article-title":"Lung cancer - non-small cell: statistics","year":"2023","journal-title":"Cancer.Net"},{"key":"10.1016\/j.vhri.2024.101004_bib4","author":"Midthun"},{"issue":"21","key":"10.1016\/j.vhri.2024.101004_bib5","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.vhri.2024.101004_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.lungcan.2006.01.006","article-title":"Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial","volume":"52","author":"Brodowicz","year":"2006","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.vhri.2024.101004_bib8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.vhri.2024.101004_bib9","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","article-title":"Paramount: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer","volume":"31","author":"Paz-Ares","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.vhri.2024.101004_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.vhri.2024.101004_bib12","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1097\/JTO.0b013e318267cf84","article-title":"Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer","volume":"7","author":"Gridelli","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.vhri.2024.101004_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/CEOR.S119818","article-title":"The cost-effectiveness of a NSCLC patient assistance program for pemetrexed maintenance therapy in People\u2019s Republic of China","volume":"9","author":"Shi","year":"2017","journal-title":"ClinicoEconomics Outcomes Res"},{"issue":"1","key":"10.1016\/j.vhri.2024.101004_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clinthera.2012.12.013","article-title":"Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system","volume":"35","author":"Zeng","year":"2013","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.vhri.2024.101004_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10198-003-0205-2","article-title":"When should decision-analytic modeling be used in the economic evaluation of health care?","volume":"4","author":"Siebert","year":"2003","journal-title":"Eur J Health Econ Formerly"},{"issue":"5","key":"10.1016\/j.vhri.2024.101004_bib16","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0272989X12455463","article-title":"State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3","volume":"32","author":"Siebert","year":"2012","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.vhri.2024.101004_bib17","first-page":"9","article-title":"Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review","volume":"7","author":"Choua\u00efd","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.vhri.2024.101004_bib18","article-title":"Pemetrexed as Maintenance Therapy for Advanced, Non-squamous, Non-small Cell Lung Cancer (NSCLC)","author":"Movik","year":"2012","journal-title":"Oslo, Norway: Knowledge Center for the Health Services at The Norwegian Institute of Public Health (NIPH)"},{"issue":"1","key":"10.1016\/j.vhri.2024.101004_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jval.2011.08.1737","article-title":"Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system","volume":"15","author":"Matter-Walstra","year":"2012","journal-title":"Value Health"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2024.101004_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3310\/hta14suppl2-05","article-title":"Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer","volume":"14","author":"Greenhalgh","year":"2010","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.vhri.2024.101004_bib21","first-page":"60","article-title":"Pharmacoeconomic analysis for pemetrexed as a maintenance therapy for NSCLC patients with patient assistance program in China","volume":"21","author":"Lu","year":"2018","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.vhri.2024.101004_bib22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1477-7525-6-84","article-title":"Health state utilities for non small cell lung cancer","volume":"6","author":"Nafees","year":"2008","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.vhri.2024.101004_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.vhri.2024.101004_bib24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Mak"},{"issue":"1","key":"10.1016\/j.vhri.2024.101004_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11584600-000000000-00000","article-title":"Calibrating models in economic evaluation: a seven-step approach","volume":"29","author":"Vanni","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.vhri.2024.101004_bib28","first-page":"1","article-title":"An omnibus approach to assess the prevalence, burden and quality of life of multiple diseases in the general population: the snapshot program in the Middle East","volume":"6","author":"El Hasnaoui","year":"2018","journal-title":"Med Res Arch"},{"issue":"1","key":"10.1016\/j.vhri.2024.101004_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227573","article-title":"Health-related quality of life among patients with type 2 diabetes mellitus in Eastern Province, Saudi Arabia: a cross-sectional study","volume":"15","author":"Alshayban","year":"2020","journal-title":"PLOS ONE"},{"issue":"2","key":"10.1016\/j.vhri.2024.101004_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s41669-021-00293-4","article-title":"Impact of a new cost-effectiveness threshold implementation on cancer formulary decisions in Jordan","volume":"6","author":"Treish","year":"2022","journal-title":"Pharmacoecon Open"},{"issue":"5","key":"10.1016\/j.vhri.2024.101004_bib31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0272989X12454579","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7","volume":"32","author":"Eddy","year":"2012","journal-title":"Med Decis Mak"},{"issue":"4","key":"10.1016\/j.vhri.2024.101004_bib32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","article-title":"AdViSHE: A validation-assessment tool of health-economic models for decision makers and model users","volume":"34","author":"Vemer","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"10.1016\/j.vhri.2024.101004_bib34","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jval.2020.12.024","article-title":"Considerations for cost-effectiveness analysis in oncology","volume":"24","author":"Cho","year":"2021","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2024.101004_bib35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1515\/ijb-2022-0056","article-title":"Causal inference for oncology: past developments and current challenges","volume":"19","author":"Moodie","year":"2023","journal-title":"Int J Biostat"},{"issue":"11","key":"10.1016\/j.vhri.2024.101004_bib36","first-page":"1086","article-title":"Do value thresholds for oncology drugs differ from\u00a0nononcology drugs?","volume":"20","author":"Bae","year":"2014","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"12","key":"10.1016\/j.vhri.2024.101004_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2022.09.2109","article-title":"PCR174 valuation of the EQ-5D-3L in Jordan","volume":"25","author":"Al Rabayah","year":"2022","journal-title":"Value Health"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:16:11Z","timestamp":1756685771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109924000372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":30,"alternative-id":["S2212109924000372"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101004","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Utility Analysis of Maintenance Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Non\u2013Small Cell Lung Cancer in Jordan","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101004"}}